Asit Parikh is a physician-scientist turned biotech chief executive who runs MOMA Therapeutics, a Cambridge, Massachusetts company built around the idea of systematically drugging molecular machines - the highly dynamic, shape-shifting proteins that most drug hunters avoid. An MD-PhD trained at Vanderbilt with clinical roots in gastroenterology, he spent two decades at Millennium and Takeda, where he helped steer the inflammatory bowel disease drug vedolizumab (Entyvio) from research to global blockbuster, before taking the CEO seat at MOMA in 2021. He has since raised a $150 million Series B and signed a roughly $2 billion partnership with Roche to push precision cancer medicines toward the clinic.
Graham Gaylor is the co-founder and CEO of VRChat Inc., the social virtual reality platform he built from a single Reddit-recruited room in 2014 into a $500M company with millions of custom avatars and hundreds of thousands of user-created worlds. A Vanderbilt-trained mathematician and software engineer who backed the original Oculus Kickstarter, Gaylor has spent over a decade building the infrastructure for human connection in virtual space - a platform where avatars meet, worlds multiply, and the line between game and community blurs entirely.
Frank D. Lee is the Chief Executive Officer and Board Director of Pacira BioSciences, a specialty pharmaceutical company pioneering non-opioid pain management solutions. A 30-year industry veteran who immigrated to the United States from South Korea, Lee built his career across Eli Lilly, Janssen, Novartis, and a 13-year tenure at Genentech where he oversaw $11 billion in global product sales. Before joining Pacira in January 2024, he led Forma Therapeutics through a transformative journey from drug-discovery startup to clinical-stage biotech, culminating in a $1.1 billion acquisition by Novo Nordisk in 2022. At Pacira, Lee is executing the '5x30' strategy - five bold objectives to transform the company into an innovative biopharma powerhouse by 2030, including advancing the PCRX-201 gene therapy for knee osteoarthritis, which has already earned FDA Regenerative Medicine Advanced Therapy (RMAT) designation.
Dan Cook is the CEO, Co-founder, and Investor at Lyten Inc, a San Jose-based deep-tech company pioneering 3D Graphene supermaterial and next-generation lithium-sulfur batteries. With over three decades spanning General Motors, NeXT Computer (under Steve Jobs), Bay Networks/Nortel, and private equity at Cerberus Capital, Cook pivoted to found Lyten in 2015 around a serendipitous discovery: trying to turn methane into clean hydrogen, the team accidentally created a revolutionary 3D graphene material. Under his leadership, Lyten has raised over $1.2 billion, shipped lithium-sulfur A-samples to automotive and military customers, announced the world's first lithium-sulfur gigafactory in Reno, Nevada, and in 2025-2026 acquired significant Northvolt assets across Europe to become one of the largest battery manufacturers on the continent.